# Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors

> **NCT05700084** · PHASE1 · UNKNOWN · sponsor: **Beijing Biostar Pharmaceuticals Co., Ltd.** · enrollment: 84 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Utidelone Capsule (Part 1)
- **DRUG:** Drug A Utidelone Capsule (Part 2: Group A-B)
- **DRUG:** Drug A Utidelone Capsule (Part 2: Group B-A)
- **DRUG:** Drug B Utidelone Injection (Part 2: Group A-B)
- **DRUG:** Drug B Utidelone Injection (Part 2: Group B-A)
- **DRUG:** Capecitabine
- **DRUG:** Utidelone Capsule (Part 3)

## Key facts

- **NCT ID:** NCT05700084
- **Lead sponsor:** Beijing Biostar Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-09
- **Primary completion:** 2025-03-09
- **Final completion:** 2025-04-09
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05700084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05700084, "Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05700084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*